DVA vs EHC
DaVita and Encompass Health Corporation, both Healthcare
Encompass Health Corporation is the larger company at $12B against $12B. On trailing earnings DVA is the cheaper of the two at a P/E of 14.9 against 20.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year DVA returned +38% against +1.5% for EHC. The RyuScore puts EHC ahead, 74 against 72 out of 100.
| Figure | DVA | EHC |
|---|---|---|
| Last close | $181 | $127 |
| Market cap | $12B | $12B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.9 | 20.6 |
| Dividend yield | n/a | 0.6% |
| 1-year return | +38% | +1.5% |
| 5-year return | +55% | +122% |
| RyuScoresector-relative, 1–10 | 72/100 | 74/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
DaVita
Revenue of $3.6B in Q2 2026, net income $265M. Its largest reported line is U.S.Dialysis With Intersegment, 56% of the disclosed total.
Encompass Health Corporation
Revenue of $1.6B in Q2 2026, net income $154M. Its largest reported line is Medicare, 64% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.